Muhammad M Bashir
Overview
Explore the profile of Muhammad M Bashir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vazquez T, Patel J, Kodali N, Diaz D, Bashir M, Chin F, et al.
J Invest Dermatol
. 2023 Dec;
144(6):1262-1272.e7.
PMID: 38086428
The immunologic drivers of cutaneous lupus erythematosus (CLE) and its clinical subtypes remain poorly understood. We sought to characterize the immune landscape of discoid lupus erythematosus and subacute CLE using...
2.
Bashir A, Bashir M, Afzaal S, Ahmad F, Choudhery M
Cell Biol Int
. 2023 Mar;
47(6):1118-1125.
PMID: 36855962
Facial contour deformities associated with pigmentary changes are of major concern for plastic surgeons being difficult to treat. No definite ideal treatment option is available to address simultaneously both the...
3.
Werth V, Hejazi E, Pena S, Haber J, Zeidi M, Reddy N, et al.
J Invest Dermatol
. 2022 May;
142(10):2651-2659.e1.
PMID: 35490744
Background: Treatment options are limited for skin disease in dermatomyositis. Lenabasum is a cannabinoid receptor type 2 agonist that triggers the resolution of inflammation. Objective: The objective of this study...
4.
Maddukuri S, Patel J, Diaz D, Chen K, Wysocka M, Bax C, et al.
Arthritis Res Ther
. 2022 Mar;
24(1):69.
PMID: 35277198
No abstract available.
5.
Maddukuri S, Patel J, Diaz D, Chen K, Wysocka M, Bax C, et al.
Arthritis Res Ther
. 2022 Jan;
24(1):12.
PMID: 34983619
Background: Lenabasum is a cannabinoid type 2 receptor (CB2R) reverse agonist that demonstrates anti-inflammatory effects in vivo and in vitro in dermatomyositis (DM) and is currently being investigated for therapeutic...
6.
Li Y, Bax C, Patel J, Vazquez T, Ravishankar A, Bashir M, et al.
Theranostics
. 2021 Jun;
11(15):7144-7158.
PMID: 34158841
Extracellular vesicles (EVs) are lipid bilayer membrane vesicles that are present in various bodily fluids and have been implicated in autoimmune disease pathogenesis. Type I interferons (IFN), specifically IFN-β, are...
7.
Chen K, Patel J, Zeidi M, Wysocka M, Bashir M, Patel B, et al.
J Invest Dermatol
. 2021 Mar;
141(8):1906-1914.e2.
PMID: 33675790
Dermatomyositis pathogenesis remains incompletely understood; however, recent work suggests a predominant IFN-1 response. We explored dermatomyositis pathogenesis by quantifying the inflammatory cells in the skin, comparing myeloid with plasmacytoid dendritic...
8.
Bashir M, Sohail M, Ahmad F, Choudhery M
Stem Cells Int
. 2019 Dec;
2019:5146594.
PMID: 31827528
Quick absorption of adipose tissue grafts makes the outcomes less satisfactory for clinical applications. In the current study, adipose tissue grafts were mixed with adipose tissue-derived stem cells (ASCs) to...
9.
10.
Alves P, Bashir M, Wysocka M, Zeidi M, Feng R, Werth V
J Investig Dermatol Symp Proc
. 2017 Sep;
18(2):S57-S63.
PMID: 28941496
Antimalarials are used to treat dermatomyositis (DM) and cutaneous lupus erythematosus (CLE). Although hydroxychloroquine (HCQ) is frequently used, addition of quinacrine (QC) has shown additional clinical effects when combined with...